Biophytis (EPA:ALBPS) | WebDisclosure

Basculer en Français

11295	Companies
251006	Keywords
179930	Articles
136867	Press releases

Home
Companies
Biophytis

REGULATED PRESS RELEASE

published on 01/08/2025 at 07:00, 1 year 10 months ago

Biophytis annonce un nouvel apport en cash et une conversion de dettes pouvant atteindre 8,6 M€ pour financer son programme dans l’obésité
Biophytis annonce un nouvel apport en cash de 2,5 M€ et une conversion de dettes jusqu'à 6,1 M€ pour financer son programme dans l'obésité. Opération de refinancement de 8,6 M€ pour consolider sa structure financière et lancer l'étude de phase 2 OBA aux États-Unis

Biophytis Financement Développement Clinique Opération Financière Obésité
REGULATED PRESS RELEASE

published on 01/08/2025 at 07:00, 1 year 10 months ago

Biophytis Announces New Cash Contribution and Debt Conversion up to €8.6 million to Finance the Obesity Program
Biophytis announces new cash contribution and debt conversion totaling €8.6 million to finance obesity program. Strategic financial transaction strengthens company's financial structure for future development

Biophytis Financial Transaction Debt Conversion Obesity Program Cash Contribution
BRIEF

published on 01/06/2025 at 08:35, 1 year 10 months ago

Biophytis suspend temporairement la cotation de ses actions pour un refinancement

Biophytis Biotechnologie Euronext Growth Refinancement Suspension De Cotation
BRIEF

published on 01/06/2025 at 08:35, 1 year 10 months ago

Biophytis Temporarily Suspends Trading of Shares Before Refinancing

Biophytis Biotechnology Refinancing Age-related Diseases Trading Suspension
REGULATED PRESS RELEASE

published on 01/06/2025 at 08:30, 1 year 10 months ago

Biophytis annonce la suspension temporaire de la cotation de ses actions et de ses BSA avant la conclusion d'une opération de refinancement
Biophytis annonce la suspension temporaire de la cotation de ses actions et de ses BSA avant la conclusion d'une opération de refinancement. Pour plus d'informations, visitez www.biophytis.com

Biophytis Biotechnologie Cotation Refinancement Suspension Temporaire
REGULATED PRESS RELEASE

published on 01/06/2025 at 08:30, 1 year 10 months ago

Biophytis announces temporary suspension of the listing of its shares and share warrants prior to the completion of a refinancing transaction
Biophytis temporarily suspends listing of shares and share warrants prior to refinancing transaction. Trading to resume soon

Biophytis Shares Refinancing Listing Suspension
BRIEF

published on 12/24/2024 at 07:05, 1 year 10 months ago

Biophytis to Attend 2025 JP Morgan Healthcare Conference in San Francisco

Biophytis Biotechnology Investment Opportunities JP Morgan Healthcare Conference Obesity Innovation
BRIEF

published on 12/24/2024 at 07:05, 1 year 10 months ago

Biophytis à San Francisco pour la JP Morgan Healthcare Conference 2025

Biophytis Partenariats San Francisco JP Morgan Healthcare Conference BioPharma Obesity Innovation Forum
REGULATED PRESS RELEASE

published on 12/24/2024 at 07:00, 1 year 10 months ago

Biophytis Will Be In San Franscico During The 2025 JP Morgan Healthcare Conference
Biophytis to attend 2025 JP Morgan Healthcare Conference in San Francisco and participate in Sachs Conference and BIO@JPM Week. The company focuses on developing treatments for age-related diseases

Biophytis Biotechnology Age-related Diseases San Francisco JP Morgan Healthcare Conference
REGULATED PRESS RELEASE

published on 12/24/2024 at 07:00, 1 year 10 months ago

Biophytis sera à San Francisco durant la JP Morgan Healthcare Conference de 2025
Biophytis participera à la JP Morgan Healthcare Conference de 2025 à San Francisco et au BioPharma Obesity Innovation Forum ainsi qu'à la conférence BIO@JPM Week, présentant ses avancées dans les traitements liés à l'âge

Biophytis Maladies Liées À L'âge Développement De Traitements JP Morgan Healthcare Conference BioPharma Obesity Innovation Forum

Accesswire

Published on 11/06/2026 at 22:15, 2 days 10 hours ago

Jaguar Health Reports Approval of All Proposals at November 2026 Special Meeting of Stockholders
Published on 11/06/2026 at 13:00, 2 days 19 hours ago

Alaska Energy Metals Achieves High Extraction Rates of Metals from Hydromet Testing, Nikolai Nickel Project, Alaska
Published on 11/06/2026 at 12:30, 2 days 20 hours ago

Relevant Gold Receives Expanded Drilling Approvals for the Lewiston Project in Wyoming
Published on 11/06/2026 at 12:30, 2 days 20 hours ago

Vogenx Reports Third Quarter 2026 Financial Results and Business Highlights
Published on 11/06/2026 at 10:00, 2 days 22 hours ago

Mongolia Tax Audit

View all ACCESSWIRE

EQS Group

Published on 11/09/2026 at 08:15, 32 minutes ago

EQS-Adhoc: Airbus SE: Airbus commences multi-year share buyback programme, with launch of the first tranche
Published on 11/09/2026 at 08:05, 42 minutes ago

Onodrim Industries secures $300 million Series A at $1.3 billion valuation to strengthen Europe's defence and industrial foundations
Published on 11/09/2026 at 08:00, 47 minutes ago

Aquis Stock Exchange: Transfer to Apex segment
Published on 11/09/2026 at 08:00, 47 minutes ago

Transaction in Own Shares
Published on 11/09/2026 at 08:00, 47 minutes ago

Custodian Property Income REIT plc: Further momentum with majority share-based acquisition strategy, purchasing an £11.0m property portfolio from eight syndicated investment vehicles

Les Echos

Published on 11/09/2026 at 07:00, 1 hour 47 minutes ago

bioMérieux receives U.S. FDA 510(k) clearance for the latest versions of the BIOFIRE® FILMARRAY® Gastrointestinal Panels to enhance detection of gastrointestinal pathogens including norovirus
Published on 11/09/2026 at 07:00, 1 hour 47 minutes ago

BIOPHYTIS ANNOUNCES THE OPERATIONAL LAUNCH OF ITS JOINT VENTURE IN CHINA
Published on 11/09/2026 at 07:00, 1 hour 47 minutes ago

Biophytis annonce le démarrage opérationnel de sa co-entreprise en Chine
Published on 11/09/2026 at 07:00, 1 hour 47 minutes ago

bioMérieux obtient l’autorisation 510(k) de la FDA américaine pour les dernières versions des tests BIOFIRE® FILMARRAY® Gastrointestinal Panels afin d’optimiser la détection des pathogènes gastrointestinaux, dont le norovirus
Published on 11/06/2026 at 19:06, 2 days 13 hours ago

ALTAREIT : DÉCLARATION MENSUELLE DES OPÉRATIONS RÉALISÉES PAR LA SOCIÉTÉ SUR SES PROPRES TITRES OCTOBRE 2026

View all LES ECHOS COMFI WIRE